Evidence map›Paper›PMID 41824195›Full record

ReviewDiscover oncology2026

Ferroptosis as a novel targeted therapy in gynecological malignant tumors.

Congxiang Yu, Yuefei Li, Yangxin Fu, Ruizhe Yang, Zorica Nakevska, Pooja Praveen Kumar, An Nhien Tong, Nan Yang, Dan Liu, Chao Chen and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Congxiang YuDepartment of Obstetrics and Gynecology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, China.
Yuefei LiDepartment of Obstetrics and Gynecology, Inner Mongolia Maternal and Child Health Care Hospital, Hohhot, 010020, Inner Mongolia, China.
Yangxin FuDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Ruizhe YangDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Zorica NakevskaDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Pooja Praveen KumarDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
An Nhien TongDepartment of Cellular Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Nan YangShengjing Hospital of China Medical University, Shenyang, 110122, Liaoning, China.
Dan LiuThe Fourth Affiliated Hospital of China Medical University, Shenyang, 110122, Liaoning, China.
Chao ChenDepartment of Gynaecology and Obstetrics, General Hospital of Northern Theater Command, Shenyang, 110122, Liaoning, China.
Ling OuyangShengjing Hospital of China Medical University, Shenyang, 110122, Liaoning, China.
Zhijun XiaObstetrics and Gynecology Hospital of Fudan University, Shanghai, 60513996, China. xiazhijun_2024@qq.com.

Funding

Program for Health Science and Technology in the Inner Mongolia Autonomous Region 202202202Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences 2024GLLH0281Youth Cultivation Project of Inner Mongolia Medical University YKD2021QN014Youth Fund Program of the Natural Science Foundation of the Inner Mongolia Autonomous Region 2022QN0826
6 · The paper itself

Abstract

Ferroptosis, an emerging form of regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic target in oncology. Gynecological malignancies—cervical, endometrial, and ovarian cancers—are frequently associated with therapeutic resistance due to defective cell death regulation. This review delineates cancer-specific ferroptosis regulatory networks across these malignancies. In cervical cancer, high-risk HPV oncoproteins (E6/E7) rewire oxidative stress and lipid metabolism, leading to stage-dependent ferroptosis vulnerability and supporting combination approaches with immunotherapy. In endometrial cancer, ELK1-mediated GPX4 upregulation drives chemoresistance, highlighting ferroptosis induction as a strategy to overcome treatment failure. In ovarian cancer, iron overload promotes metastasis, while p53, lipid-modifying enzymes (SCD1/FADS2), and the tumor microenvironment (e.g., CXCL8/CXCR2 axis) modulate ferroptosis sensitivity, providing avenues to target aggressive subtypes such as clear cell carcinoma. We conclude that targeting ferroptosis offers a transformative strategy for gynecological cancers.

Indexed as

Cervical carcinomaEndometrial carcinomaFerroptosisGlutathione peroxidase 4GynecologicalMalignant tumorsOvarian carcinoma

Identifiers

PMID41824195
PMCPMC13222908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.